Phytochemical Analysis and Anti-Inflammatory and Anti-Osteoarthritic Bioactive Potential of Verbascum thapsus L. (Scrophulariaceae) Leaf Extract Evaluated in Two In Vitro Models of Inflammation and Osteoarthritis

Osteoarthritis (OA) is a complex disease, source of pain and disability that affects millions of people worldwide. OA etiology is complex, multifactorial and joint-specific, with genetic, biological and biomechanical components. Recently, several studies have suggested a potential adjuvant role for natural extracts on OA progression, in terms of moderating chondrocyte inflammation and following cartilage injury, thus resulting in an overall improvement of joint pain. In this study, we first analyzed the phenylethanoid glycosides profile and the total amount of polyphenols present in a leaf aqueous extract of Verbascum thapsus L. We then investigated the anti-inflammatory and anti-osteoarthritic bioactive potential of the extract in murine monocyte/macrophage-like cells (RAW 264.7) and in human chondrocyte cells (HC), by gene expression analysis of specifics inflammatory cytokines, pro-inflammatory enzymes and metalloproteases. Six phenylethanoid glycosides were identified and the total phenolic content was 124.0 ± 0.7 mg gallic acid equivalent (GAE)/g of extract. The biological investigation showed that the extract is able to significantly decrease most of the cellular inflammatory markers, compared to both control cells and cells treated with Harpagophytum procumbens (Burch.) DC. ex Meisn, used as a positive control. Verbascum thapsus leaf aqueous extract has the potential to moderate the inflammatory response, representing an innovative possible approach for the inflammatory joint disease treatment.     

Transient phosphorylation of tumor associated microtubule associated protein (TMAP)/cytoskeleton associated protein 2 (CKAP2) at Thr-596 during early phases of mitosis

Tumor associated microtubule associated protein (TMAP), also known as cytoskeleton associated protein 2 (CKAP2) is a mitotic spindle-associated protein whose expression is cell cycle-regulated and also frequently deregulated in cancer cells. Two monoclonal antibodies (mAbs) against TMAP/CKAP2 were produced: B-1-13 and D-12-3. Interestingly, the reactivity of mAb D-12-3 to TMAP/CKAP2 was markedly decreased specifically in mitotic cell lysate. The epitope mapping study showed that mAb D-12-3 recognizes the amino acid sequence between 569 and 625 and that phosphorylation at T596 completely abolishes the reactivity of the antibody, suggesting that the differential reactivity originates from the phosphorylation status at T596. Immunofluorescence staining showed that mAb D-12-3 fails to detect TMAP/CKAP2 in mitotic cells between prophase and metaphase, but the staining becomes evident again in anaphase, suggesting that phosphorylation at T596 occurs transiently during early phases of mitosis. These results suggest that the cellular functions of TMAP/CKAP2 might be regulated by timely phosphorylation and dephosphorylation during the course of mitosis.     

Ubiquitylation of Fe65 adaptor protein by neuronal precursor cell expressed developmentally down regulated 4-2 (Nedd4-2) via the WW domain interaction with Fe65

Fe65 has been characterized as an adaptor protein, originally identified as an expressed sequence tag (EST) corresponding to an mRNA expressed at high levels in the rat brain. It contains one WW domain and two phosphotyrosine interaction/phosphotyrosine binding domains (PID1/PID2). As the neuronal precursor cell expressed developmentally down regulated 4-2 (Nedd4-2) has a putative WW domain binding motif (⁷²PPLP⁷⁵) in the N-terminal domain, we hypothesized that Fe65 associates with Nedd4-2 through a WW domain interaction, which has the characteristics of E3 ubiquitin-protein ligase. In this paper, we present evidence for the interaction between Fe65 WW domain and Nedd4-2 through its specific motif, using a pull down approach and co-immunoprecipitation. Additionally, the co-localization of Fe65 and Nedd4-2 were observed via confocal microscopy. Co-localization of Fe65 and Nedd4-2 was disrupted by either the mutation of Fe65 WW domain or its putative binding motif of Nedd4-2. When the ubiquitin assay was performed, the interaction of Nedd4-2 (wt) with Fe65 is required for the cell apoptosis and the ubiquitylation of Fe65. We also observed that the ubiquitylation of Fe65 (wt) was augmented depending on Nedd4-2 expression levels, whereas the Fe65 WW domain mutant (W243KP245K) or the Nedd4-2 AL mutant (⁷²PPLP⁷⁵ was changed to ⁷²APLA⁷⁵) was under-ubiquitinated significantly. Thus, our observations implicated that the protein-protein interaction between the WW domain of Fe65 and the putative binding motif of Nedd4-2 down-regulates Fe65 protein stability and subcellular localization through its ubiquitylation, to contribute cell apoptosis.     

High‐resolution differentiation of transmissible spongiform encephalopathy strains by quantitative N‐terminal amino acid profiling (N‐TAAP) of PK‐digested abnormal prion protein

New forms of transmissible spongiform encephalopathy (TSE) continue to be identified, and consequently sensitive differential diagnosis is increasingly important both for the management of disease in humans and livestock and in providing confidence in the safety of the food chain. TSE diseases are associated with accumulation of protease‐resistant prion protein (PrP^Sc) and detection of this marker protein is central to diagnosis. Proteolysis by proteinase K (PK) generates protease‐resistant products (PrP^res) with partially variable N‐termini. The conformation(s) of PrP^Sc and thus the points of PK cleavage are thought to be dependent on the strain of prion disease. Western blot (WB) analysis of PrP^res gives characteristic migration patterns that can be used to diagnose TSEs, but the relatively low resolution of this technique limits its ability to differentiate certain disease strains. Mass spectrometry (MS) has the capability to resolve these various PK cleavage sites to the level of individual amino acid residues. In the present study multiple selected reaction monitoring (mSRM) was used to detect and quantify PrP^res N‐terminal tryptic peptides by MS and thus to define the N‐terminal amino acid profiles (N‐TAAPs) of PrP^res characteristic for various TSEs in sheep. The fragmentation behaviour of the N‐terminal tryptic peptides was studied to allow selection of the transitions specific for each peptide. Different PrP^res preparation methods were evaluated and the most effective approach applied to differentiate the N‐TAAPs corresponding to various sheep TSE isolates. Marked differences were identified between the N‐TAAPs of bovine spongiform encephalopathy (BSE) and classical scrapie, and between classical scrapie and the experimental strains SSBP/1 and CH1641, thereby validating this approach as a means of TSE‐strain specific diagnosis. Copyright © 2008 John Wiley & Sons, Ltd.     

聚(2-甲基-2-噁唑啉)在毛细管电泳分离蛋白质中的应用

毛细管电泳作为一种常见的液相分离技术,因其分析速度快、分离效率高、样品消耗量少等特点,在蛋白质分离分析领域有广泛应用。然而,常用的熔融硅毛细管容易吸附蛋白质,导致电渗流不稳定,分离结果重现性变差;此外,商用毛细管电泳中常用的紫外检测器由于光程短,使得毛细管电泳的检测灵敏度往往不能达到低丰度蛋白质的直接分析要求。因此寻找能够阻止蛋白质吸附、同时能够提高检测灵敏度的涂层是毛细管电泳分离分析蛋白质的重要课题之一。聚（2-甲基-2-噁唑啉）（PMOXA）作为一种类肽类亲水性聚合物,具有与抗蛋白质吸附聚合物聚乙二醇类似的亲水性、抗蛋白质吸附性和生物相容性,而且其类肽结构使之具有较聚乙二醇更好的稳定性,因此近年来在生物质传递、药物载体和阻抗蛋白质吸附等领域得到越来越多的应用。该文主要从两个方面对聚（2-甲基-2-噁唑啉）在毛细管电泳中的应用进行了阐述。一是利用多巴胺作为黏合层将其涂覆在毛细管内壁作为抗蛋白质吸附涂层,这种涂层不仅能成功分离多种蛋白质的混合物（如溶菌酶、细胞色素C、核糖核酸酶A和α-胰凝乳蛋白酶原A）,而且在定量检测奶粉中三聚氰胺、乳铁蛋白的过程中,能阻抗其他蛋白质的非特异性吸附,提高了毛细管电泳对奶粉中三聚氰胺、乳铁蛋白的检测效率。二是将其与具有刺激响应性的聚合物（如聚丙烯酸）构成二元混合刷涂层,在一定的pH和离子强度条件下,涂层可吸附目标蛋白质（如牛血清白蛋白、溶菌酶）,在另一pH和离子强度条件下可将吸附的目标蛋白质全部释放,同时在释放过程中,处于涂层表面的聚（2-甲基-2-噁唑啉）会进一步阻止蛋白质的吸附,释放的蛋白质在电渗流和电泳的双重作用下快速迁移,到达检测器的蛋白质瞬时浓度大大增加,使目标蛋白质得到富集,目标蛋白质的检测信号得到放大,从而达到了提高低丰度蛋白质检测灵敏度的目的。此外,该文还对聚（2-甲基-2-噁唑啉）在毛细管电泳分离蛋白质中的未来发展趋势进行了展望。     

Targeting tribbles homolog 3 (TRIB3) protein against type 2 diabetes for the identification of potential inhibitors by in silico screening

Tribbles homolog 3 (TRIB3) protein is inhibiting the insulin signaling by directly binding to the Akt/PKB leading to insulin resistance in the pancreas causing type 2 diabetes mellitus. Hence, TRIB3 protein is considered as a possible drug target for the new lead identification against type 2 diabetes. In the present study, the homology model of TRIB3 protein was generated to explore its biochemical function and molecular interactions in the new lead identification. The energy minimization of TRIB3 protein was carried out and evaluated by validation protocols for structure reliability. The druggable binding site of TRIB3 protein was identified for the virtual screening and molecular docking studies. The Asinex-fragments library of 22634 small molecules was docked at TRIB3 active site using the Glide module to identify new chemical entities. A total of 9 molecules were identified as final hits from virtual screening and their potency was ranked using Glide score, Glide energies, and residues interactions. The 6 prioritized lead molecules were further optimized using AutoDock, Prime MM/GBSA, and percentage of human oral absorption for the identification of potential leads. The molecules L2, L5, and L6 are identified as lead inhibitors and are showing consistent interactions with key residues Glu194 and Lys196 of TRIB3 protein. The identified potential leads were analyzed by ADME properties for their drug likeness and HergIC50 values are predicted for the prevention of preclinical failures. The present work sheds light on the identification of the best lead molecules against TRIB3 protein and offers a route to design as novel potential drug candidates for T2DM.     

Total protein determinations by particle beam/hollow cathode optical emission spectroscopy (PB/HC-OES) system III: Investigation of carrier salts for enhanced particle transport

Particle beam hollow cathode optical emission spectroscopy (PB/HC-OES) is evaluated as a generic tool for total protein determinations by monitoring the carbon atomic emission (C (I) 193.0 nm) resultant from dissociated analyte species. Previous studies demonstrated the capability of the PB/HC-OES system for total protein determinations with limits of detection for bovine serum albumin (BSA) samples being at the single-nanogram level for 200 l injections. Non-linear behavior across the concentration range in the calibration curve was observed due to the poor transport of small particles (owing to low analyte concentrations) through the PB interface. The potential use of non-volatile salts as carrier agents is investigated in the determination of protein samples by PB/HC-OES. A range of chloride salts (different cations), potassium salts (different anions), and an organic modifier (ammonium acetate) is investigated here for possible use as carriers upon addition as sample injection matrices for protein samples. The analyte response curves of BSA samples with KCl added as the sample injection matrix show higher sensitivity, better linearity (R²) and subsequently lower detection limits in comparison to those obtained with water, HCl, KNO₃ or ammonium acetate as carrier matrices.     

Studies of the surface layer structure and properties of poly(styrene/α-t-butoxy-ω-polyglycidol) microspheres by carbon nuclear magnetic resonance,X-ray photoelectron spectroscopy,and the adsorption of human serum albumin and γ-globulins

The composition and properties of the surface layers of poly(styrene/α-t-butoxy-ω-polyglycidol) [poly(styrene/VB-polyGL)] microspheres synthesized by the radical copolymerization of styrene and α-t-butoxy-ω-vinylbenzyl-polyglycidol (VB-polyGL) macromonomers [number-average molecular weight (M_n) = 950 or 2700] were investigated with X-ray photoelectron spectroscopy, ¹³C NMR, and the adsorption of human serum albumin and γ-globulins. The number-average diameter of the synthesized microspheres was 220 nm. Their surface layers were rich in polyglycidol, with polyglycidol-to-polystyrene unit ratios of 0.443 (VB-polyGL with M_n = 950) and 0.427 (VB-polyGL with M_n = 2700). In suspensions of poly(styrene/VB-polyGL) particles in D₂O, the polymer chains in the polyglycidol-rich surface layers were highly mobile, allowing the registration of polyglycidol ¹³C NMR spectra with standard procedures for polymer solutions. In these spectra, the signals of the relatively immobile polystyrene segments were absent. The spin–lattice relaxation times (T₁) measured for polyglycidol in the microsphere surface layers and for VB-polyGL macromonomers in solution were very close, indicating similar degrees of motion in bound (in particle surface layers) and free (in solution) polyglycidol macromolecules. Studies of protein adsorption revealed that hydrophilic polyglycidol layers were protein-repellent. It was found that longer polyglycidol chains in particle surface layers were more mobile (higher T₁ values) and provided better protection against protein adsorption. © 2003 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 42: 615–623, 2004     

Evaluation of isotope-coded protein labeling (ICPL) in the quantitative analysis of complex proteomes

An evaluation of the ICPL (isotope-coded protein labeling) non-isobaric labeling technique was performed using two different biological models. Two samples containing phage T4 capsids were mixed in a 1:1 ratio after being labeled with the light or heavy versions of the ICPL reagent. The analysis of this proteome demonstrated the feasibility of this approach for differential quantitative proteomics and was employed to optimize the experimental parameters of the ICPL workflow. ICPL-mediated analysis of two more complex proteomes, those of a Salmonella enterica serovar Typhimurium virulent strain and an isogenic attenuated mutant, and its comparison with the results obtained in a 2D-PAGE “classical” approach confirmed that ICPL is a valuable alternative to other labeling techniques currently in use. In addition, our results suggest that labeling at the peptide level instead of following the standard ICPL workflow should increase both the number of proteins quantified and the reliability of the quantification.     

Nonlinear calibrations on the assay of dilitiazem and two of its metabolites from plasma samples by means of liquid chromatography and ESI/MS(2) detection: application to a bioequivalence study

The assay of diltiazem (DLTZ) and its active metabolites desacetyldiltiazem (DAcD) and desmethyldiltiazem (DMeD) in plasma samples was achieved by means of an HPLC/(ESI)MS(2) method. The diastereoisomer of diltiazem, namely {(2R,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate} was used as internal standard (IS). Sample preparation was based on protein precipitation by means of organic solvent addition (acetonitrile). The isocratic elution based on a reversed-phase mechanism allows good separation of the analytes within 15 min. Atmospheric pressure electrospray ionization was used. All analytes were monitored in the MS(2)-MRM mode. A fragmentation schema is proposed for the target compounds. As the method was designed for bioequivalence purposes, a full validation procedure was considered. On validation, nonlinear calibrations were observed. Consequently, concentration intervals requiring nonlinear calibrations are discussed. Low limits of quantification in the 0.6-1 ng/mL concentration range were obtained. The analytical method was successfully applied to a single dose (120 mg), open-label, randomized, two-period, two-sequence, crossover bioequivalence study of two commercially available solid oral dosage pharmaceutical formulations (tablets).     

Development of Protein‐Cage‐Based Delivery Nanoplatforms by Polyvalently Displaying β‐Cyclodextrins on the Surface of Ferritins Through Copper(I)‐Catalyzed Azide/Alkyne Cycloaddition

Protein cages are spherical hollow macromolecules that are attractive platforms for the construction of nanoscale cargo delivery vehicles. Human heavy‐chain ferritin (HHFn) is modified genetically to control the number and position of functional groups per cage. 24 β‐CDs are conjugated precisely to the modified HHFn in specific locations through thiol‐maleimide Michael‐type addition followed by copper(I)‐catalyzed azide/alkyne cycloaddition (CuAAC). The resulting human ferritins displaying β‐CDs (β‐CD‐C90 HHFn) can form inclusion complexes with FITC‐AD, which can slowly release the guest molecule reversibly in a buffer solution via non‐covalent β‐CD/AD interactions. β‐CD‐C90 HHFn can potentially be used as delivery vehicles for insoluble drugs.